Healthcare Nov 30, 2021 07:48 AM (GMT+8) · EqualOcean
Financial Associated Press, Nov. 30 - Hengrui pharmaceutical announced on Monday evening that it had received a regulatory letter to clarify regulatory requirements on relevant matters. Insiders disclosed that Hengrui's announcement in the evening is about the regulatory requirements for the treatment of "capitalization of R & D expenses". It is clear that it is necessary to carefully evaluate whether the capitalization conditions are met and the collection of R & D expenses should be accurate and complete. It belongs to the daily performance of duties of the exchange and does not involve administrative penalties.

This text is a result of machine translation.

Related companies：